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Abstract
Objective: Regulatory T cells (Tregs) are known to infiltrate the tumour microenvironment of many cancers,
including head and neck malignancies, and are thought to contribute to the host's impaired anti-tumour immune
response. However, their immunosuppressive function remains poorly understood within the tumour
microenvironment and this study aimed to address this.
Methods: The frequency and suppressive capacity of two CD4+CD127low/- Treg populations, separated on the
basis of different levels of CD25 expression (CD25inter and CD25high), from the tumour/node microenvironment and
peripheral circulation of newly-presenting head and neck squamous cell carcinoma patients (n=19), were assessed
using multicolour flow cytometry.
Results: The proportion of Tregs (CD4+CD25high/interCD127low/-) in the tumour/node microenvironment was
significantly elevated compared with the peripheral circulation (p<0.001) and similar percentages were present in
both the primary tumour and metastatic lymph node. The percentage of suppression induced by Tregs isolated from
tumour associated nodes on the proliferation of nodal effector T cells was similar to that of peripheral Tregs on
peripheral effector T cells. However, when the suppressive activity of both nodal and peripheral Tregs was
compared on the same peripheral effectors, peripheral Tregs suppressed proliferation to a greater extent.
Conclusion: This work shows that the recruitment and percentages of tumour infiltrating Tregs are key factors in
modulating the immune environment of head and neck tumours.
Keywords: CD127low/-; HNSCC; Regulatory T cells; Tumour
infiltrating lymphocytes
Abbreviations:
CFSE: Carboxyfluorescein Diacetate Succinimidyl Ester; Foxp3:
Forkhead box transcription factor p3; HNSCC: Head and Neck
Squamous Cell Carcinoma; IL: Interleukin; PBMC: Peripheral Blood
Mononuclear Cells; TIL: Tumour Infiltrating Lymphocytes; Tregs:
Regulatory T cells
Introduction
Head and neck cancer is the sixth most common type of cancer
worldwide [1] and encompasses a number of epithelial malignancies
that develop from anatomically defined locations within the upper
aerodigestive tract. Although united by general location and histology,
head and neck squamous cell carcinomas (HNSCC) arise from
different primary sites and vary in presentation, pathogenesis and
prognosis. Although recent reports have shown improved prognosis
and survival for head and neck tumours positive for the human
papillomavirus [2,3], and despite advances in surgical and adjuvant
chemoradiotherapy treatment strategies, the overall survival rate of
HNSCC patients has not significantly improved over the last 30 years.
Treatment failure is almost always associated with locoregional
recurrence and/or the development of distant metastases.
HNSCC patients are widely recognised as having a suppressed
immune system thought to be mediated through a variety of
mechanisms including, the presence of functionally defective
circulating and tumour infiltrating lymphocytes that have enhanced
levels of apoptosis [4,5] and increased suppression induced by
regulatory T cells (Tregs) [6,7]. In addition, the tumour mass itself also
appears to promote an immunosuppressive environment [8,9]. Whilst
investigations in the peripheral circulation of cancer patients offers an
indication of the effects the tumour is exerting upon the host’s
systemic immune system, direct examination of the tumour
microenvironment provides a detailed insight into the localised anti-
tumour immune responses implemented by the host and the immune
evasion strategies employed by the tumour.
The tumour microenvironment consists of a complex network of
epithelial cells, stroma, chemical secretions, vascular and lymphatic
vessels, and a plethora of infiltrating immune cells, whose actions
range from promotion to inhibition of tumour growth and
progression [10]. The infiltration of Tregs into the tumour is thought
to contribute to the host's impaired anti-tumour response and
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promote an immunosuppressive environment, with the ability to
suppress the function of antigen presenting cells and effector T cells
[11]. Although the infiltration of Tregs has been assessed by many
research groups in several different cancer types, including HNSCC,
there are conflicting reports over whether the presence of Tregs are
associated with better locoregional control [12], negative prognosis
[13], or of no relevance at all [14], and requires further clarification if
prognostic or therapeutic value is to be gained.
Assessing Tregs in the tumour microenvironment as a prognostic
indicator has to date focussed solely on their frequency and several
publications, including HNSCC studies, have observed an increased
prevalence of Tregs infiltrating malignant tissue compared with the
peripheral circulation of cancer patients [7,15-18]. However, when
assessing the contribution of the Treg population their suppressive
activity should also be investigated, as both frequency and function
may contribute to how effective a host's anti-tumour response will be
in combating the growth and progression of the tumour. Although
tumour infiltrating Tregs have been shown to possess suppressive
activity [19-22], only limited investigations exist, in human cancers,
which have compared the suppressive activity of the circulating and
infiltrating Treg populations [7,16,23]. To our knowledge this is the
first study to use the CD4, CD25 and CD127 markers to examine both
the frequency and function of tumour infiltrating and peripheral Tregs
from newly-presenting HNSCC patients.
Materials and Methods
Patients and healthy donors
Characteristics Number
HNSCC patients sex and age
Male 16
Female 3
Mean age (years) 60
Age range (years) 41-84
Sample site
Primary tumour 4
Tumour associated lymph node 15
Tumour stage
Early (T1 and T2) 4
Advanced (T3 and T4) 12
Unknown 3
Primary tumour site
Laryngeal 9
Oropharyngeal 6
Hypopharyngeal 2
Unknown 2
Table 1: Clinicopathological features of HNSCC patients whose
tumour samples were assessed for Treg frequency and function.
Following ethical and NHS Trust approval (Yorkshire and the
Humber research ethics committee; REC-10/H1304/7, HEY NHS
Trust-R0988) and having obtained written informed consent, newly-
presenting HNSCC patients that had not received previous radio- or
chemotherapy prior to sample collection were recruited onto the study
(n=19; Table 1). Patients who had received diagnosis or treatment for
any other form of cancer, had active autoimmune or co-existing
infectious disease were excluded from the study. The tissue specimens
included 4 samples from the primary tumour site and 15 samples from
tumour associated lymph nodes; 15 of the 19 patients recruited
provided both blood and tissue for analysis.
Isolation of peripheral blood mononuclear cells
A 50 ml venous blood sample was taken into a heparin coated
syringe from each HNSCC patient prior to surgery. Peripheral blood
mononuclear cells (PBMC) were isolated by density gradient
centrifugation using lymphocyte separation medium (PAA, Yeovil,
UK), as described previously [24]. Isolated PBMC were re-suspended
in freeze medium [foetal bovine serum (FBS; Biosera, East Sussex, UK)
containing 10% v/v dimethyl sulfoxide (Sigma, Dorset, UK)] for
cryopreservation and subsequent use in the assessment of Treg
frequency and function.
Isolation of tumour infiltrating lymphocytes
Freshly isolated tumour specimens were collected during resection
surgery and transported to the laboratory in Dulbecco's Modified
Eagle's Medium (DMEM; PAA), supplemented with 10% (v/v) FBS
(Biosera), 0.4 mM L-glutamine, penicillin/streptomycin (final
concentrations: 0.1 U/ml and 0.1 mg/ml, respectively; PAA) and
fungizone (2.5 µg/ml; Invitrogen, Paisley, UK). Following removal of
fat, blood and necrotic areas, the HNSCC samples were minced into 1
mm3 pieces using scalpels, whilst covered in medium. After an
antibiotic wash (PBS plus fungizone and penicillin/streptomycin as
above), the tumour fragments were dissociated for 2 hours at 37ºC in
medium containing 0.02% (w/v) DNase (type 1; Roche Diagnostics,
Burgess Hill, UK) and 0.02% (w/v) collagenase (type IV; Sigma) whilst
under constant rotation (MACSmixTM Tube Rotator; Miltenyi Biotec,
Bisley, UK). Following incubation the dissociated tumour fragments
were washed three times in medium and cultured in 25 cm3 culture
flasks overnight at 37°C to enable the majority of fibroblasts, epithelial
cells and monocytes to adhere to the plastic. The medium, containing
tumour infiltrating lymphocytes (TIL), was then collected and cells
were isolated by centrifugation for immediate use in fluorescent
activated cell sorting to assess the suppressive function of Tregs, or
were cryopreserved until analysis at a later date.
Treg and effector T cell characterisation and isolation by
flow cytometry
Tregs and effector T cells within cryopreserved PBMC and freshly
isolated/cryopreserved TIL were labelled using the human regulatory
T cell sorting kit (BD Biosciences, Oxford, UK). Lymphocytes (1 ×
104) were acquired and gated using forward and side scatter
characteristics and, following doublet discrimination, a CD4 vs CD25
dot plot was created to determine the different levels of CD25
expression (CD25inter and CD25high) [6]; CD4+ T cells exceeding the
level of CD25 expression by CD4- T cells were defined as the
CD4+CD25high population. Using these boundaries and the level of
CD127 expression by CD4+ lymphocytes both Tregs
(CD4+CD25interCD127low/- and CD4+CD25highCD127low/-) and
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effector T cells (CD4+CD25-CD127-/+) were identified and isolated [6].
The prevalence of Tregs was expressed as a percentage of the total
CD4+ population (mean ± SEM).
Suppression assay
The suppressive activity of isolated Tregs on the proliferation of
autologous effector T cells was determined by a co-culture
carboxyfluorescein diacetate succinimidyl ester (CFSE) assay, as
described previously [6]. Briefly, effector T cells (CD4+CD25-
CD127-/+) were stained with 5 µM of CFSE (Sigma) and the labelling
quenched with ice cold culture medium. Following incubation on ice
for 5 minutes and washes with pre-warmed medium, the labelled
effector T cells were co-cultured with Tregs
(CD4+CD25interCD127low/- and CD4+CD25highCD127low/-) in 200µl of
culture medium at various ratios (range Treg:effector T cells; 1:1–
1:10).Where possible the CFSE assay was performed with 5 x 104
effector cells cultured in each well of a 96 well round bottomed plate,
however, when insufficient cells were isolated, the number of effector
cells plated was successfully scaled down to 1 x 104/well. Lymphocyte
stimulation was provided by Human T-Activator CD3/CD28
dynabeads (Invitrogen) at a cell:bead ratio of 1:3 and 100 U/ml
recombinant human IL-2 (AbD Serotec, Kidlington, UK).
Following four days of co-culture, the cells were harvested and the
proliferation of the CFSE labelled effector T cells was determined
using flow cytometry. All CFSE data was analysed using ModFit LTTM
software (Verity Software House, Topsham, USA) to calculate the
proliferation index. The percentages of suppression were determined
based on the proliferation index for effector cells cultured alone (100%
proliferation, 0% suppression) compared with the proliferation index
of effector cells co-cultured with Tregs.
Statistical analysis
Statistical analysis was performed using SPSS version 19. The
normality of the data was assessed by the Shapiro-Wilk test.
Differences between independent data sets, with normal distribution,
were analysed using the Student's unpaired T test with the assumption
of equal variance assessed by the Levene's test. The Mann-Whitney U
test was used for data sets without normal distribution. Differences
between related data sets were analysed using the Student's paired T
test and the Wilcoxon Signed Rank test for data sets normally or not
normally distributed respectively. Values were considered significant
when p<0.05.
Results
Prevalence of Tregs in the tumour microenvironment and
peripheral circulation of HNSCC patients
To compare the prevalence of Tregs between the tumour
microenvironment and the peripheral circulation, tumour samples
from both the primary tumour site and tumour associated lymph
nodes were analysed alongside the patient's corresponding PBMC
sample. The proportion of CD4+ lymphocytes with the CD127low/-
Treg phenotype, irrespective of the level of CD25 expression, was
significantly elevated in the tumour/node microenvironment
compared with that in the peripheral circulation (Figure 1a). This
significant increase in the tumour/node microenvironment was
maintained in the patients with laryngeal tumours when the patient
cohort was divided by tumour subsite (Figure 1b), but only reached
significance for the CD4+CD25highCD127low/- (termed CD25high)
Tregs in patients with oropharyngeal cancers (Figure 1b). The trend
was maintained for patients with cancer of the hypopharynx however,
due to the low number of samples (n=2) this subsite was not
statistically assessed.
Figure 1: (a) Percentage of CD4+CD25interCD127low/-(CD25inter)
and CD4+CD25highCD127low/-(CD25high) Tregs in the tumour/
node microenvironment and peripheral circulation of HNSCC
patients (*p<0.001). (b) Percentage of CD25inter and CD25high Tregs
from patients with tumours arising from different HNSCC subsites
(laryngeal and oropharyngeal) in the tumour/node
microenvironment and peripheral circulation (*p<0.001; **p=0.01;
***p=0.04).
There was no difference in the proportion of
CD4+CD25interCD127low/- (termed CD25inter) and CD25high Tregs
infiltrating the primary tumour tissue (n=4) compared with the
tumour associated lymph nodes (n=15; Table 2), and no significant
difference in the percentages of infiltrating CD25inter and CD25high
populations was observed between the laryngeal (n=9) and
oropharyngeal tumours (n=6).
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Treg phenotype Primary tumourtissue (n=4)
Tumour
associated lymph
node (n=15)
p value
CD25inter 18.7 ± 1.7 16.9 ± 1.2 0.97
CD25high 21.2 ± 7.1 19.1 ± 2.0 0.65
Mean percentage ± SEM
Table 2: Frequency of Tregs in the tumour microenvironment of
HNSCC patients.
Suppressive activity of CD127low/- Tregs in the tumour
microenvironment of HNSCC patients
Previous results have shown that the level of suppression induced
by peripheral CD25inter and CD25high Tregs on peripheral effector T
cell proliferation is ratio dependent [6]. The same was true in the
current study when Tregs and effector T cells, both isolated from the
tumour associated nodes, were incubated together at various ratios
(Figure 2). Due to the size of the primary tumour biopsies it was only
possible to isolate sufficient Tregs to establish a 1:1 Treg:effector T cell
ratio. This condition was used for statistical analysis of differences
between various cell populations and clinicopathological parameters.
When the suppressive activity of Tregs isolated from tumour
associated lymph nodes was related to tumour subsite, no significant
differences in the level of suppression were observed between the
laryngeal and oropharyngeal cohorts, irrespective of the Treg
population being analysed (data not shown). Relationships with other
clinical parameters (tumour stage, nodal status) were not examined as
the majority of samples were late stage and node positive.
Figure 2: Mean percentage of suppression induced by nodal
CD25inter and CD25high Tregs on the proliferation of autologous
nodal CD4+CD25-CD127-/+ effector T cells at various Treg:effector
T cell ratios.
Suppressive activity of CD127low/- Tregs in the tumour
microenvironment compared with Tregs from the peripheral
circulation of HNSCC patients
No difference was observed in the basal proliferation index of
effector T cells isolated from the tissue microenvironment (6.1 ± 0.6)
compared with that of those from the peripheral circulation (6.8 ± 0.6)
meaning that direct comparisons could be made.
Both CD25inter and CD25high Tregs isolated from tumour associated
nodes induced similar levels of suppression on autologous nodal
effector T cells (24.3 ± 5.0 and 27.1 ± 4.0%, respectively) when
compared with peripheral Tregs on peripheral effector T cells from the
same patients (26.8 ± 5.8 and 18.8 ± 4.5%, respectively). Similar levels
of suppression were also observed by the Tregs obtained from the
primary tumour samples on their tumour effector counterparts,
however, due to the low number of samples (n=2) the data could not
be statistically assessed.
To determine whether the close proximity of the tumour
microenvironment influences the susceptibility of the effector T cell
population to Treg induced suppression, Tregs isolated from the
tumour associated lymph nodes were co-cultured with autologous
effector T cells isolated from both the tumour infiltrated node and the
peripheral circulation. Irrespective of the Treg population analysed
(CD25inter and CD25high) the co-culture of nodal Tregs with nodal
effector T cells produced higher percentages of suppression compared
with the incubation of nodal Tregs with peripheral effectors, however
these differences did not quite reach significance (Table 3).
Nodal Treg
population
Co-culture with
nodal effector T
cells (n=10)
Co-culture with
peripheral effector
T cells (n=10)
p value
CD25inter 24.3 ± 5.0 17.2 ± 4.0 0.15
CD25high 27.1 ± 4.0 14.1 ± 4.6 0.09
Mean percentage ± SEM
Table 3: Comparing the percentage of suppression induced by nodal
Tregs on the proliferation of autologous nodal and peripheral effector
T cells in HNSCC patients.
Figure 3: Mean percentage of suppression induced by nodal and
peripheral CD25inter and CD25high Tregs on the proliferation of
autologous peripheral CD4+CD25-CD127-/+ effector T cells at a 1:1
Treg:effector T cell ratio (*p=0.01).
To determine the suppressive function of Tregs isolated from
tumour associated lymph nodes and those from the peripheral
circulation, Tregs from the two different environments were each co-
cultured with autologous peripheral effector T cells. It was
demonstrated that, regardless of the level of CD25 expression, the
percentages of suppression induced by peripheral Tregs was always
greater than nodal Tregs. This difference reached significance for the
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CD25inter Treg population (Figure 3). Due to insufficient immune cell
numbers being available from the biopsies the suppressive function of
nodal and peripheral Tregs on the proliferation of tumour infiltrated
lymph node effector T cells could not be determined.
Discussion
Tumour infiltrating Tregs have been identified in numerous cancer
types, however their role in tumour immunity and their use as a
prognostic determinant remains to be clarified [10,12-14]. The aim of
the current study was to understand better the Treg population
infiltrating the head and neck tumour microenvironment and the
influence of the tumour on these T cells, by assessing their frequency
and suppressive activity in comparison to those found in the
periphery. To the authors knowledge this is the first study to examine
both the frequency and function of CD127low/- Tregs infiltrating the
tumour microenvironment of newly-presenting HNSCC patients. In
addition the suppressive activity of Tregs, of any phenotype, from
tumour associated lymph nodes has not previously been assessed in
HNSCC.
The proportion of lymphocytes which displayed the Treg
phenotype (CD25inter or CD25high) was similar in both the tumour
infiltrated lymph nodes and the primary tumour of HNSCC patients,
and no significant difference was found between subsites. This is in
agreement with Pretscher et al. who reported similar frequencies of
Foxp3+ (forkhead box transcription factor p3) Tregs infiltrating the
primary tumour and metastatic lymph nodes of HNSCC patients using
immunohistochemistry, implying that the metastasised tumour
recruits Tregs in a similar manner to the primary tumour [25].
Irrespective of whether the Tregs expressed high or intermediate
levels of CD25, their frequency was significantly elevated in the
tumour/node microenvironment of HNSCC patients compared with
that in the peripheral circulation of the same patient. When studying
subsites, the laryngeal cohort showed this trend for both CD25inter and
CD25high Tregs, whereas in samples from oropharyngeal patients only
the CD25high tumour Tregs remained statistically raised compared
with those in the peripheral circulation. Similar studies in gastric and
hepatocellular cancer patients also found significantly elevated
proportions of CD4+CD25+CD127low/-and CD4+CD25+CD127low/-
CD49d- Tregs respectively, in TIL compared with the peripheral
circulation [18,26]. In head and neck cancer patients Strauss and
colleagues also reported a significantly higher level of CD4+CD25high
and CD4+CD25+ Tregs in the tumour microenvironment (n=15)
compared with the peripheral circulation (n=14) of patients, despite
only five of the fifteen patients providing matched tumour and PBMC
samples [7]. The matching of the tumour and peripheral samples used
in the current study helped to minimise any potential influence of
clinicopathological features.
The significant increase of Tregs in TIL compared with that in the
peripheral circulation has also been reported in several other cancer
types [15-17], and suggests that the tumour may be recruiting or
expanding the suppressive Treg population, both mechanisms having
been demonstrated in murine and human studies, along with the
induction of Tregs from naïve precursors [27-30]. One attractive
theory is that the elevated frequency of Tregs observed in tumour
associated lymph nodes could arise from the expansion of lymph node
resident Tregs [31]. However, a significant correlation between the
degree of CCL22 and/or CCL17 positive cells and the frequency of
Tregs in the tumour microenvironment of breast, oesophageal and
gastric cancer patients has been reported [30,32,33], supporting the
evidence that chemokines are involved in the recruitment of the Treg
population to the primary tumour [19,32,33].
In addition to the frequency of Tregs their level of suppressive
activity is likely to contribute to overall immune suppression. During
the quest to find a unique marker to identify Tregs, it has been
reported that those expressing high levels of the IL-2 receptor
(CD4+CD25high) had the capacity to inhibit effector T cell
proliferation compared with T cells expressing intermediate/low levels
of CD25 [34]. The current study demonstrated that CD127low/- Tregs,
with both intermediate and high levels of CD25 expression, isolated
from either tumour associated lymph nodes or the primary tumour
site of HNSCC patients had an equivalent ability to suppress the
proliferation of the classic CD4+CD25- effector T cell population,
frequently used by other research groups [7,16,21].
No significant differences were observed between the level of
suppression induced by nodal infiltrating Tregs and peripheral Tregs
on the proliferation of effector T cell populations derived from the
same compartment. This is in agreement with Chi et al. who found no
significant differences between the regulatory function of Tregs
isolated from the PBMC (n=10) and TIL (n=10) of bladder carcinoma
patients when co-cultured with their autologous effector T cells at a 1:1
ratio [16].
Although it was hypothesised that Tregs isolated from the tumour
microenvironment would induce a significantly greater level of
suppression as a result of direct influences from the tumour to
promote mechanisms to thwart the host's anti-tumour immune
response, the current study suggests that in fact the peripheral Tregs
(particularly those with the CD25inter phenotype) had the greater
suppressive activity than nodal Tregs when the level of suppression
was measured on autologous peripheral effector T cells. This is in
contrast to a recent study by Jie et al. who demonstrated, in only a
single patient, that peripheral and tumour infiltrating Tregs
(CD4+CD25+) induced similar levels of suppression on effector T cell
proliferation when incubated at a 1:1 ratio, and in a second patient the
suppressive activity of the tumour derived Tregs was greater [23].
The fact that there was a trend towards a higher level of suppression
of the nodal effectors by the nodal Tregs, as compared with their
suppression induced on peripheral effectors would suggest that the
tumour microenvironment causes the infiltrating effector T cells to
become more susceptible to the actions of the tumour Tregs. There
was no significant difference between the proliferation index of
effector cells from the tumour and those from the periphery and so
this was a real observed effect.
In summary, Tregs are significantly elevated in the tumour
microenvironment of newly-presenting HNSCC patients compared
with their peripheral circulation, regardless of primary tumour site.
For the first time CD127low/- Tregs have been identified and isolated
from the TIL of head and neck cancer patients and it has been
demonstrated that the level of suppression induced by tumour/node
infiltrating Tregs and peripheral Tregs on the proliferation of their
effector T cell populations from the same compartment was similar.
However, when the suppressive activity of both peripheral and nodal
Tregs was studied on peripheral effector T cells, infiltrating Tregs were
observed to be less suppressive compared with peripheral Tregs
despite their close proximity to the suppressive tumour
microenvironment. However, it is likely that there is an overall greater
level of suppression induced by Tregs in the tumour
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microenvironment compared with the peripheral circulation due to
both the elevation of the proportion of Tregs infiltrating the tumour
and other cytokine influences acting directly on T effector cells [35].
This study together with other recent work has highlighted the
complexity of Treg function. Thus for research in this area to make a
significant impact on patient outcome, well powered investigations,
using precisely defined cell populations are needed.
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